Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.

  title={Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.},
  author={Ilse G C Hermsen and Harm R. Haak and Ronald R. de Krijger and Thomas Kerkhofs and Richard A. Feelders and Wouter W. de Herder and Hanneke W. Wilmink and Jan W. A. Smit and Hans Gelderblom and Noel F.C.C. de Miranda and Ronald van Eijk and Tom van Wezel and Hans Morreau},
  journal={European journal of endocrinology},
  volume={169 1},
BACKGROUND Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis and limited therapeutic options. Mitotane is considered the standard first-line therapy with only 30% of the patients showing objective tumour response. Defining predictive factors for response is therefore of clinical importance. The epidermal growth factor receptor (EGFR) has been implicated in the development of one-third of all malignancies. EGFR pathway members in ACC have been investigated, however, without… 

Figures and Tables from this paper

Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma
The combination of Erlotinib and NVP-AEW541 enhances anti-tumour efficacy compared to treatment with either agent alone or to untreated control in vitro and vivo and may be considerable for treatment of ACC in the future.
Past, Present and Future of Epigenetics in Adrenocortical Carcinoma
Recent findings on epigenetic alterations in the process of adrenal tumorigenesis are rapidly increasing and will add to a better understanding of the pathogenesis of ACC.
Genetics and epigenetics of adrenocortical tumors
Curcumin induces apoptosis and inhibits the growth of adrenocortical carcinoma: Identification of potential candidate genes and pathways by transcriptome analysis
Curcumin inhibited the viability, migration and invasion, and induced the apoptosis of ACC cells, and inhibited tumour growth by activating the JNK, p38 MAPK and ER stress pathways.
Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
Adrenocortical carcinoma is a rare malignancy with poor prognosis and limited response to chemotherapy. Hepatocyte growth factor (HGF) and its receptor cMET augment cancer growth and resistance to
The PI3K/Akt Pathway in Tumors of Endocrine Tissues
This review explores the growing evidence from multiple animal and in vitro models and from analysis of human tumors for the involvement of this pathway in the following cancer types and reviews active Akt as a potential prognostic marker and the PI3K pathway as a therapeutic target in endocrine neoplasia.
Adrenocortical carcinoma : a study on epidemiology diagnostics and treatment of a rare endocrine malignancy
This dissertation describes the prevalence of this disease and the survival rate among adults and children in the Netherlands and examines a diagnostic tool that uses a urine test to distinguish between benign and malignant tumours in the adrenal gland.
Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition
Findings indicate that β-catenin loss in H295R cells inhibits tumor growth by inducing transcriptional and functional changes.
Adrenocortical carcinoma: modern management and evolving treatment strategies.
This review focuses on recent literature published in the field of ACC from 2010 to 2015 with an emphasis on improving diagnosis, staging and treatment for ACC.
A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature
A case of a 22-year-old female patient who was diagnosed with a cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC), the first featuring two somatic APC mutations underlying the disease, with an overview of CMV- PTC cases with detected APC and CTNNB1 pathogenic variants from the literature.


Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome
The results suggest that EGFR expression in adrenocortical tumors indicates a malignant phenotype, which may be used in the differential diagnosis between adrenoc Cortical adenomas and carcinomas.
β-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma
Wnt/β-catenin activation, confirmed by the presence of β-Catenin nuclear staining, is an independent prognostic factor of overall and disease-free survival in patients with resected primary ACC.
Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
Inhibitors of the Ras/Raf/MEK/ERK and EGFR pathways represent candidate targeted therapies for future clinical trials in carefully selected patients with adrenocortical carcinomas harboring respective activating mutations.
Investigation of BRAFand CTNNB1 activating mutations in adrenocortical tumors
Activating BRAF somatic mutations may be occasionally found in advanced adrenocortical carcinomas, while CTNNB1 activating mutations are early and common events in adrenal tumorigenesis.
The impact of epidermal growth factor receptor gene status on gefitinib‐treated Japanese patients with non‐small‐cell lung cancer
It is suggested that the CA‐SSR1 length may influence the clinical outcome in patients with a drug‐sensitive EGFR mutation and the high EGFR copy number may not be related to clinical benefits in gefitinib‐treated Japanese patients with NSCLC.
Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival.
Gene expression analysis unravels two distinct groups of adrenocortical carcinomas and identifies molecular predictors of malignancy and of survival that are reliable and provide valuable independent information in addition to pathology and tumor staging.
Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer
The results indicate that the Akt, but not necessarily EGFR, is one of the most important target in the response of the platinum-based chemotherapy and prognosis for ovarian cancer patients.
Molecular determinants of cetuximab efficacy.
  • D. Vallböhmer, Wu Zhang, H. Lenz
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
This pilot study suggests that gene expression levels of Cox-2, EGFR, IL-8, and VEGF in patients with metastatic CRC may be useful markers of clinical outcome in single-agent cetuximab treatment.
p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.
It is concluded that p53 plays a role in the tumorigenesis of adrenocortical carcinomas but is of less importance to benign adenomas.
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.